By Phil Serafino Sept. 30 (Bloomberg) -- Sanofi's Jevtana drug was rejected by the UK's health-cost agency as a treatment for prostate cancer in patients for whom an older medicine didn't work. Jevtana is too costly given "uncertainty" about its hearts ... Sanofi's Jevtana Cancer Drug Rejected by UK Cost Agency
Thursday, September 29, 2011
Sanofi's Jevtana Cancer Drug Rejected by UK Cost Agency
By Phil Serafino Sept. 30 (Bloomberg) -- Sanofi's Jevtana drug was rejected by the UK's health-cost agency as a treatment for prostate cancer in patients for whom an older medicine didn't work. Jevtana is too costly given "uncertainty" about its hearts ... Sanofi's Jevtana Cancer Drug Rejected by UK Cost Agency
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment